Clinical Trial Update: Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating bevacizumab in combination with paclitaxel versus paclitaxel with placebo as first-line therapy for HER2-negative metastatic breast can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Metastatic Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2016-02-10